Navigation Links
Solid tumor cells not killed by radiation and chemotherapy become stronger
Date:6/9/2008

DURHAM, N.C. Because of the way solid tumors adapt the body's machinery to bring themselves more oxygen, chemotherapy and radiation may actually make these tumors stronger.

"In a sense, these therapies can make the tumor healthier," said Mark W. Dewhirst, D.V.M., Ph.D., professor of radiation oncology at Duke University Medical Center. "Unless the treatment is very effective in killing many if not most tumor cells, you are shooting yourself in the foot."

Dewhirst and colleagues Yiting Cao, M.D., Ph.D., of Duke Pathology, and Benjamin Moeller, M.D., Ph.D. have introduced this counter-intuitive idea at recent conferences and in a review article featured in the June issue of Nature Reviews Cancer.

Radiation and chemotherapy do kill most solid tumor cells, but in the cells that survive, the therapies drive an increase in a regulatory factor called HIF1 (hypoxia-inducible factor 1), which cells use to get the oxygen they need by increasing blood vessel growth into the tumor. Solid tumors generally have low supplies of oxygen, Dewhirst explained and HIF1 helps them get the oxygen they need.

The review article concludes that blocking HIF1 would provide a clear mechanism for killing solid-tumor cells, particularly cells that are proving resistant to radiation or chemotherapy treatments.

As a part of this work, Dewhirst's team has been studying the phenomenon of rising and falling oxygen levels in tumors, called cycling hypoxia. Oxygen levels have been found to naturally cycle up and down in individual blood vessels as well as large tumor regions. This instability in the tumor's oxygen levels can increase HIF-1 production and cause radiation therapy to fail, Dewhirst said.

"It is my opinion that the whole tumor grows more aggressively because of this pulsation of oxygen at low levels," Dewhirst said. "Most people thought cycling hypoxia was caused by temporary stoppage of blood flow in single blood vessel in tumors. In fact, however, oxygen levels cycle up and down virtually everywhere in the tumor, which is caused by fluctuations in blood flow rate. It has been a challenge to convince people of this."

Dewhirst and colleagues have made movies of oxygen transport in a tumor of a living animal that show the oxygen levels cycle up and down significantly, pulsing in waves seen as color changes in the movies. (View these movies at the Nature Reviews Cancer site: http://www.nature.com/nrc/journal/v8/n6/suppinfo/nrc2397.html )

The Duke team argues that blocking HIF1 is the consistent answer to tumor growth problems. Blocking HIF1 activity interferes with the tumor's ability to undergo glycolysis (energy production) in low-oxygen conditions, which blocks tumor growth, the authors wrote. Exactly how to accomplish chemotherapy or radiation treatment in the safest, most effective ways, in combination with HIF1 blockade, is still open for exploration, Dewhirst said.

For example, targeting HIF1 in the early stages of tumor growth, especially in very early cancer spread, may help, Dewhirst said. "For a woman who has had a primary breast tumor removed, and who is at high risk for cancer spread, this might be a situation in which you'd target HIF1," he explained. "Blocking HIF1 makes sense during the early stages of angiogenesis, which is the accelerated phase of blood vessel formation. In this way, you could keep the early metastasis sites inactive and prevent them from growing."

The Duke team has completed a phase I trial with a HIF1 inhibitor. "We are actively pursuing this clinically and will be moving this study into Phase 2," Dewhirst said. "We are interested in other applications of HIF-1 inhibition in combination with radiation and chemotherapy for different diseases."


'/>"/>

Contact: Mary Jane Gore
mary.gore@duke.edu
919-660-1309
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. MedAmerica Reports Solid Growth, Outperforms Industry
2. Insurance Department to Hold Statewide Meetings on Proposed Consolidation of Independence Blue Cross, Highmark
3. STAAR Surgical Reports Solid First Quarter Progress
4. Life Sciences Discovery Fund Awards $2.2 Million to Support New Solid-Tumor Research Program
5. A long-term survival offered by resection of solid-pseudopapillary tumor of the pancreas?
6. New target for cancer therapy may improve treatment for solid tumors
7. Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President
8. Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007
9. SAFC Pharma Expands Its Pharmorphix Solid State Chemistry Services
10. Insurance Department Will Hold Public Hearings on Proposed Consolidation of Highmark, Independence Blue Cross
11. James E. Harris to Become Chief Financial Officer of Coca-Cola Bottling Co. Consolidated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2017)... ... April 30, 2017 , ... ... the importance of substantially reducing melanoma and non-melanoma skin cancer through education by ... a collaboration between the American Academy of Dermatology and Pediatric Sun Protection Foundation, ...
(Date:4/30/2017)... Aliso Viejo, CA (PRWEB) , ... April 30, ... ... liquid animations created exclusively for use in Final Cut Pro X. Editors can ... bursts and more. Easily change the highlights, mid levels and shadows using simple ...
(Date:4/30/2017)... Louis, MO (PRWEB) , ... April 30, 2017 , ... ... a sharp increase in projected attendance for this year’s physician career fairs, with this ... , The complete schedule for the 2017 calendar year of national physician career fairs ...
(Date:4/30/2017)... , ... April 30, 2017 , ... San Francisco Dental ... to announce an updated blog post on the continual issue of the importance of ... seek a second opinion before dental surgery, but this can be a serious mistake. ...
(Date:4/29/2017)... ... April 29, 2017 , ... BECK ... launch of DonorBridge, its process and engagement analytics application built specifically for ... industry expertise with predictive analytics to help nonprofits operate more intelligently and ...
Breaking Medicine News(10 mins):
(Date:4/28/2017)... Inc. ("Hill-Rom") (NYSE: HRC ) today ... ended March 31, 2017, and raised its outlook ... guidance reflect the contribution from the Mortara Instrument ... 14, 2017.  For the fiscal second ... share compared to $0.33 per diluted share in ...
(Date:4/26/2017)... Phoenix Marketing Solutions ( Phoenix ) ... mission of transforming science into clinical practice. During a time ... innovative approach supports the life sciences industry by ... in science and medicine — which ultimately improves lives. ... 2002 by Tracy Doyle and Angela Fiordilino ...
(Date:4/25/2017)... Endo International plc (NASDAQ: ENDP ) will announce its ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 6086379. Please dial in 10 minutes prior to the scheduled start ... call will be available from May 9, 2017 at 11:30 a.m. ...
Breaking Medicine Technology: